{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T21:10:46Z","timestamp":1759785046637,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["31571069"],"award-info":[{"award-number":["31571069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Emil & Wera Cornell\u2019s Foundation and Center for Innovative Medicine"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.brainresbull.2019.04.026","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T20:29:39Z","timestamp":1556569779000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Citalopram attenuates social behavior deficits in the BTBR T+Itpr3tf\/J mouse model of autism"],"prefix":"10.1016","volume":"150","author":[{"given":"Yulong","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Nalvarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainresbull.2019.04.026_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbr.2011.10.032","article-title":"Differences in BTBR T+ tf\/J and C57BL\/6J mice on probabilistic reversal learning and stereotyped behaviors","volume":"227","author":"Amodeo","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/aur.1395","article-title":"Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf\/J mice","volume":"7","author":"Amodeo","year":"2014","journal-title":"Autism Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbr.2016.06.064","article-title":"M100907 attenuates elevated grooming behavior in the BTBR mouse","volume":"313","author":"Amodeo","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/gbb.12343","article-title":"5HT2A receptor blockade in dorsomedial striatum reduces repetitive behaviors in BTBR mice","volume":"16","author":"Amodeo","year":"2017","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/aur.1901","article-title":"The adenosine A2A receptor agonist, CGS 21680, attenuates a probabilistic reversal learning deficit and elevated grooming behavior in BTBR mice","volume":"11","author":"Amodeo","year":"2018","journal-title":"Autism Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014","volume":"67","author":"Baio","year":"2018","journal-title":"Surveill. Summ."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000173","article-title":"Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder","volume":"25","author":"Bishop","year":"2015","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1017\/S1461145701002280","article-title":"Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study","volume":"4","author":"Buchsbaum","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0045","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.pbb.2010.09.012","article-title":"Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism","volume":"97","author":"Chadman","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0050","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/17460441.2017.1383982","article-title":"Animal models for autism in 2017 and the consequential implications to drug discovery","volume":"12","author":"Chadman","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13229-017-0130-3","article-title":"Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism","volume":"8","author":"Chen","year":"2017","journal-title":"Mol. Autism"},{"issue":"November (13)","key":"10.1016\/j.brainresbull.2019.04.026_bib0060","first-page":"1","article-title":"Prevalence and characteristics of autism Spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2012","volume":"65","author":"Christensen","year":"2018","journal-title":"Surveill. Summ."},{"issue":"Suppl. 2","key":"10.1016\/j.brainresbull.2019.04.026_bib0065","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/sj.mp.4001167","article-title":"Role of altered brain serotonin mechanisms in autism","volume":"7","author":"Chugani","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0070","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nn.3927","article-title":"Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression","volume":"18","author":"Chung","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0075","article-title":"Citalopram versus other anti-depressive agents for depression","author":"Cipriani","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-005-0166-5","article-title":"Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test","volume":"183","author":"Crowley","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0085","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/sj.npp.1301065","article-title":"Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test","volume":"31","author":"Crowley","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0090","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1038\/s41598-018-31385-7","article-title":"The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism","volume":"8","author":"Eissa","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0095","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ar.21318","article-title":"Deconstructing sociability, an autism-relevant phenotype, in mouse models","volume":"294","author":"Fairless","year":"2011","journal-title":"Anat. Rec."},{"issue":"3","key":"10.1016\/j.brainresbull.2019.04.026_bib0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0278-5846(82)80180-2","article-title":"Kinetics of citalopram in test animals; drug exposure in safety studies","volume":"6","author":"Fredricson Over\u00f8","year":"1982","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/pharmacy6020043","article-title":"Comprehension of Top 200 prescribed drugs in the US as a Resource for pharmacy teaching, training and practice","volume":"6","author":"Fuentes","year":"2018","journal-title":"Pharmacy"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archpsyc.59.5.425","article-title":"Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy","volume":"59","author":"Furmark","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.euroneuro.2014.02.004","article-title":"Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis","volume":"24","author":"Gabriele","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.neuropharm.2016.02.025","article-title":"Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine","volume":"105","author":"Golub","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1471-4159.2010.07104.x","article-title":"Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf\/J mouse social behavior","volume":"116","author":"Gould","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.psyneuen.2013.09.003","article-title":"Enhanced novelty-induced corticosterone spike and upregulated serotonin 5-HT1A and cannabinoid CB1 receptors in adolescent BTBR mice","volume":"39","author":"Gould","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/aur.1665","article-title":"Serotonin neuron abnormalities in the BTBR mouse model of autism","volume":"10","author":"Guo","year":"2017","journal-title":"Autism Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1542\/pir.35.2.62","article-title":"The clinician\u2019s guide to autism","volume":"35","author":"Harrington","year":"2014","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jemermed.2008.06.030","article-title":"Comparison of toxicity of acute overdoses with citalopram and escitalopram","volume":"39","author":"Hayes","year":"2010","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/aur.1955","article-title":"The effect of physical activity interventions on youth with autism spectrum disorder: a meta-analysis","author":"Healy","year":"2018","journal-title":"Autism Res."},{"year":"2018","series-title":"Risk and Protective Factors Underlying Depression and Suicidal Ideation in Autism Spectrum disorder. Depress Anxiety","author":"Hedley","key":"10.1016\/j.brainresbull.2019.04.026_bib0155"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.15.15","article-title":"Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders","volume":"16","author":"Helton","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0170","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s10803-006-0324-6","article-title":"Hyperserotonemia in adults with autistic disorder","volume":"37","author":"Hranilovic","year":"2007","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008372.pub2","article-title":"Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents","author":"Hurwitz","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-015-4115-7","article-title":"Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism","volume":"233","author":"Kazdoba","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4088\/JCP.v67n0311","article-title":"Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability","volume":"67","author":"Kolevzon","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.psychres.2009.02.008","article-title":"Relationship between whole blood serotonin and repetitive behaviors in autism","volume":"175","author":"Kolevzon","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.psychres.2014.09.018","article-title":"Self-injury in autism spectrum disorder: an effect of serotonin transporter gene promoter variants","volume":"220","author":"Kolevzon","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0205","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1021\/acs.jmedchem.7b00965","article-title":"Targets for drug therapy for autism Spectrum disorder: challenges and future directions","volume":"60","author":"Lacivita","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neubiorev.2013.11.009","article-title":"Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects","volume":"38","author":"Mahar","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0215","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00004583-199807000-00017","article-title":"Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation","volume":"37","author":"McBride","year":"1998","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1601-183X.2007.00330.x","article-title":"Autism-like behavioral phenotypes in BTBR T+tf\/J mice","volume":"7","author":"McFarlane","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026077","article-title":"mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism","volume":"6","author":"Mehta","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.expneurol.2017.02.004","article-title":"Zebrafish models of autism spectrum disorder","volume":"299","author":"Meshalkina","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145709990630","article-title":"Differential effects of acute and repeated citalopram in mouse models of anxiety and depression","volume":"13","author":"Mombereau","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuroscience.2015.11.010","article-title":"The serotonin system in autism spectrum disorder: from biomarker to animal models","volume":"321","author":"Muller","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0250","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1601-183X.2004.00071.x","article-title":"Automated apparatus for quantitation of social approach behaviors in mice","volume":"3","author":"Nadler","year":"2004","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aur.109","article-title":"A pharmacogenetic study of escitalopram in autism spectrum disorders","volume":"3","author":"Owley","year":"2010","journal-title":"Autism Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0260","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/jnc.14227","article-title":"16p11.2 deletion syndrome mice perseverate with active coping response to acute stress - rescue by blocking 5-HT2A receptors","volume":"143","author":"Panzini","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1601-183X.2010.00659.x","article-title":"Motor and cognitive stereotypies in the BTBR T+tf\/J mouse model of autism","volume":"10","author":"Pearson","year":"2011","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0270","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.1970.01750060086009","article-title":"Increased blood serotonin and platelets in early infantile autism","volume":"23","author":"Ritvo","year":"1970","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2040-2392-4-37","article-title":"A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders","volume":"4","author":"Rose\u2019meyer","year":"2013","journal-title":"Mol. Autism"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0280","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1601-183X.2010.00623.x","article-title":"Unusual repertoire of vocalizations in adult BTBR T+tf\/J mice during three types of social encounters","volume":"10","author":"Scattoni","year":"2011","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbr.2012.12.028","article-title":"Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf\/J strain, a mouse model of autism","volume":"251","author":"Scattoni","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0290","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0022-3476(61)80261-8","article-title":"Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children","volume":"58","author":"Schain","year":"1961","journal-title":"J. Pediatr."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0295","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/da.10112","article-title":"Citalopram treatment of social anxiety disorder with comorbid major depression","volume":"17","author":"Schneier","year":"2003","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2018.05.007","article-title":"Autism Spectrum Disorder classification, diagnosis and therapy","author":"Sharma","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0305","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neubiorev.2017.05.029","article-title":"A review of the role of serotonin system genes in obsessive-compulsive disorder","volume":"80","author":"Sinopoli","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0310","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.chc.2008.06.003","article-title":"Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders","volume":"17","author":"Soorya","year":"2008","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0315","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijdevneu.2016.08.007","article-title":"Perinatal exposure to the selective serotonin reuptake inhibitor citalopram alters spatial learning and memory, anxiety, depression, and startle in Sprague-Dawley rats","volume":"54","author":"Sprowles","year":"2016","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0320","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","volume":"11","author":"Sturman","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10803-005-3305-2","article-title":"Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism","volume":"35","author":"Sugie","year":"2005","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0330","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/npp.2011.185","article-title":"Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments","volume":"37","author":"Veenstra-VanderWeele","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0335","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1073\/pnas.1112345109","article-title":"Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior","volume":"109","author":"Veenstra-VanderWeele","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0340","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archgenpsychiatry.2009.42","article-title":"Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior","volume":"66","author":"Volkmar","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0345","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0350","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1007\/s00213-015-4058-z","article-title":"Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system","volume":"232","author":"Wang","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0355","doi-asserted-by":"crossref","first-page":"11459","DOI":"10.1038\/ncomms11459","article-title":"Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0360","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ebch.804","article-title":"Cochrane review: selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","volume":"6","author":"Williams","year":"2011","journal-title":"Evid. Child Health A Cochrane Rev. J."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0365","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11940-010-0091-8","article-title":"Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders","volume":"12","author":"Wink","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0370","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/cap.2013.0099","article-title":"Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole","volume":"24","author":"Wink","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0375","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/dmcn.13717","article-title":"Progress in the genetics of autism spectrum disorder","volume":"60","author":"Woodbury-Smith","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0380","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1185\/03007990802303525","article-title":"Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population","volume":"24","author":"Wu","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0385","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2017.08.029","article-title":"Allosteric modulation of nicotinic and GABAA receptor subtypes differentially modify autism-like behaviors in the BTBR mouse model","volume":"126","author":"Yoshimura","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainresbull.2019.04.026_bib0390","doi-asserted-by":"crossref","first-page":"k1674","DOI":"10.1136\/bmj.k1674","article-title":"Autism spectrum disorder: advances in diagnosis and evaluation","volume":"361","author":"Zwaigenbaum","year":"2018","journal-title":"BMJ"}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923018307196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923018307196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:35:26Z","timestamp":1759782926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0361923018307196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":78,"alternative-id":["S0361923018307196"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2019.04.026","relation":{},"ISSN":["0361-9230"],"issn-type":[{"type":"print","value":"0361-9230"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Citalopram attenuates social behavior deficits in the BTBR T+Itpr3tf\/J mouse model of autism","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2019.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}